Clinicopathological findings of tubulointerstitial nephritis: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR)
- PMID: 40335816
- DOI: 10.1007/s10157-025-02685-w
Clinicopathological findings of tubulointerstitial nephritis: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR)
Abstract
Introduction: Tubulointerstitial nephritis (TIN) is an important disease involving a diverse set of factors that can cause both acute kidney injury and chronic kidney disease. The purpose of this cross-sectional study was to clarify the causative diseases and clinicopathological characteristics of TIN using the Japan Renal Biopsy Registry (J-RBR).
Methods: This cross-sectional study analyzed data from 22,049 cases registered in the J-RBR between 2018 and 2022. Clinicopathological findings at diagnosis were investigated.
Results: Of the enrolled cases, 913 were diagnosed with TIN. "Drug-induced" was the most common (232 cases, 25.7%), followed by "IgG4-related kidney disease" (124 cases, 13.7%). Of "Drug-induced" TIN cases, "Chemotherapy-related" was the most common cause (63 cases, 27.2%), including 47 cases of "immune checkpoint inhibitor (ICI)-associated" TIN. IgM-positive plasma cell-rich TIN (IgMPC-TIN), which has been the focus of much attention in recent years, was also included, with 9 cases.
Conclusion: This is the first report of the clinicopathological findings of TIN patients in a large-scale, nationwide registry of renal biopsies. It was possible to identify recent trends in causative diseases, including an increase in chemotherapy-related TIN and IgMPC-TIN.
Keywords: Clinicopathological features; Etiology; IgM-positive plasma cell-rich TIN (IgMPC-TIN); Immune checkpoint inhibitor (ICI)-associated TIN; Renal biopsy; Tubulointerstitial nephritis (TIN).
© 2025. The Author(s), under exclusive licence to Japanese Society of Nephrology.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no conflict of interest. Ethical approval: All procedures performed in the J-RBR involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB Approval Number H2023-233 at the Ethics Committee of Mie University) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent: Informed consent was obtained from all participants included in this study.
References
-
- Cortazar FB, Marrone ka, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;9(3):638–47. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
